ATAI Life Sciences Appoints New Director, Adjusts CMO Compensation

Ticker: ATAI · Form: 8-K · Filed: Apr 30, 2025 · CIK: 1840904

Atai Life Sciences N.V. 8-K Filing Summary
FieldDetail
CompanyAtai Life Sciences N.V. (ATAI)
Form Type8-K
Filed DateApr 30, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: management-change, compensation

TL;DR

ATAI board shakeup: Rao out, von Ferber in. CMO Perez gets $450k base + equity.

AI Summary

On April 24, 2025, ATAI Life Sciences N.V. reported the departure of Director Srinivas Rao and the appointment of Dr. Josef von Ferber as a new director. The company also announced a new compensatory arrangement for its Chief Medical Officer, Dr. Christopher Perez, which includes a base salary of $450,000 and potential equity awards.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy and governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in key leadership and executive compensation can introduce uncertainty regarding future strategic direction and operational stability.

Key Numbers

  • $450,000 — CMO Base Salary (New annual base salary for Dr. Christopher Perez.)

Key Players & Entities

  • ATAI Life Sciences N.V. (company) — Registrant
  • Srinivas Rao (person) — Departing Director
  • Josef von Ferber (person) — Appointed Director
  • Christopher Perez (person) — Chief Medical Officer
  • $450,000 (dollar_amount) — Chief Medical Officer's base salary

FAQ

Who has departed from the ATAI Life Sciences N.V. board of directors?

Srinivas Rao has departed from the board of directors.

Who has been appointed as a new director to the ATAI Life Sciences N.V. board?

Dr. Josef von Ferber has been appointed as a new director.

What is the new base salary for ATAI's Chief Medical Officer?

The new base salary for Dr. Christopher Perez is $450,000.

What is the effective date of the reported events?

The earliest event reported is dated April 24, 2025.

What other compensatory arrangements are mentioned for the Chief Medical Officer?

In addition to his base salary, Dr. Christopher Perez is eligible for potential equity awards.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 30, 2025 by Srinivas Rao regarding ATAI Life Sciences N.V. (ATAI).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.